Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lipocine

3.14
-0.0209-0.66%
Volume:4.65K
Turnover:14.36K
Market Cap:16.80M
PE:-3.09
High:3.14
Open:3.10
Low:3.05
Close:3.16
Loading ...

Lipocine Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jun

Lipocine Announces Filing of New Drug Submission for Tlando® in Canada

THOMSON REUTERS
·
09 Jun

Lipocine: Announces Filing of New Drug Submission for Tlando® in Canada

THOMSON REUTERS
·
09 Jun

Lipocine Inc. Announces Filing of New Drug Submission for TLANDO® in Canada by Partner Verity Pharma

Reuters
·
09 Jun

Lipocine Inc. Conducted Annual Shareholder Meeting

Reuters
·
05 Jun

Lipocine Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
29 May

Buy Rating for Lipocine Driven by Innovative Drug Delivery and Promising Pipeline

TIPRANKS
·
29 May

Lipocine Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $8

THOMSON REUTERS
·
29 May

Lipocine’s LPCN 1148 Gains Fast Track Designation

TIPRANKS
·
22 May

Lipocine Inc. to Present at A.G.P.'s Annual Healthcare Company Showcase

Reuters
·
14 May

Lipocine Updates Corporate Presentation for Stakeholders

TIPRANKS
·
13 May

Lipocine Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Lipocine Reports Q1 2025 Financial Results

TIPRANKS
·
08 May

Lipocine Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $93.86K Miss $370.00K Estimate

Benzinga
·
08 May

Lipocine Inc - Reports Net Loss of $1.9 Million for Q1 2025

THOMSON REUTERS
·
08 May

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

THOMSON REUTERS
·
08 May

Lipocine Announces License and Supply Agreement for Tlando® in Brazil

THOMSON REUTERS
·
06 May

Lipocine Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
05 May

Lipocine Inc. Reports 2024 Financial Turnaround

TIPRANKS
·
04 Apr

BRIEF-Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Reuters
·
26 Mar